Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290071 | 0.83 | CYP3A4 (0.56) | CYP3A4CA1CA2TDP1MAPT | |
| SCHEMBL6292891 | 0.82 | CHRM2 (0.45) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL6292892 | 0.81 | CYP3A4 (0.49) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL6292867 | 0.79 | CYP3A4 (0.52) | CYP3A4CA1CA2TDP1TRPV1 | |
| SCHEMBL14102774 | 0.77 | CYP3A4 (0.75) | CYP3A4CA1CA2TDP1MAPT | |
| Hydrochloric Acid SCHEMBL6289116 | 0.77 | CYP3A4 (0.44) | CYP3A4CA1CA2TRPV1 | |
| SCHEMBL6292885 | 0.77 | CYP3A4 (0.53) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL9118035 | 0.76 | CYP3A4 (0.60) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL7207224 | 0.74 | TDP1 (0.69) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL24521598 | 0.74 | CYP3A4 (0.58) | CYP3A4CA1CA2TDP1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6870065-B2 | Bifunctional boronic compound complexing reagents and complexes | CAMBREX BIO SCIENCE ROCKLAND, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | AHLEM CLARENCE N (US) | 2003-06-05 | — | — | US | disclosed |
| EP-0915832-B1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX INC (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6414122-B1 | BIOCHEMICAL CONJUGATION TO PROTEINS, PEPTIDES, HORMONES, POLYSACCHARIDES, NUCLEIC ACIDS, LIPOSOMES, RADIONUCLIDES, HAPTENS, AND TOXINS | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6156884-A | Bifunctional boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0915832-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5877297-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5872224-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5837878-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5777148-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998005627-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | CHN2, CFH, COG2 | CYP3A4 853/4885CA1 470/4885CA2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.